Skip to content

Comparison of Efficacy and Safety of Remimazolam-Alfentanil Combination and Ciprofol for Sedation During Colonoscopy:a randomized controlled trial

Comparison of Efficacy and Safety of Remimazolam-Alfentanil Combination and Ciprofol for Sedation During Colonoscopy:a randomized controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070996
Enrollment
Unknown
Registered
2023-04-28
Start date
2023-05-10
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colonoscopy

Interventions

Sponsors

Liaoning Provincial People' Hospitai
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Patients who plan to undergo colonoscopy; (2) Age range from 18 to 65 years old, gender is not limited; (3) Body mass index (BMI) 18-30kg /m2; (4) American Society of Anesthesiologists (ASA) grade ? ~ ?; (5) Colonoscopy time within 30 minutes.

Exclusion criteria

Exclusion criteria: (1) Patients who refuse to participate in the trial; (2) Patients with a history of serious heart, brain, lung, liver, or kidney diseases. (LVEF40ml/min) (3) Preoperative systolic blood pressure of hypertensive patients > 180mmHg and/or diastolic blood pressure > 110mmHg, or low blood pressure 100 times/min; (5) anemia patients; (6) Patients are suspected who abuse narcotic analgesics or sedatives; (7) Those who predict that difficult airway may occur or have occurred before; (8) Those who are known to be allergic to the proposed drug; (9) Pregnant and lactating women; (10) Uncooperative, unable to communicate.

Design outcomes

Primary

MeasureTime frame
Colonoscopy success rate;

Secondary

MeasureTime frame
gender;age;height;weight;BMI;ASA grade;Blood pressure;Heart rate;oxygen saturation;Induction time;Operating time;Recovery time;Discharge time;Incidence of hypotension;Number of intraoperative supplementary remedial drugs;Total dosage of remazolam;Intraoperative adverse reactions;Postoperative adverse reaction;Satisfaction degree;Injection pain;Postoperative follow-up;

Countries

China

Contacts

Public ContactWangchangming

Liaoning Provincial People' Hospital

TeamWangCM@163.com+86 17702486100

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026